Physiological Effect: Decreased Histamine Release

Drugs with Physiological Effect: Decreased Histamine Release

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	ALOCRIL	nedocromil sodium	SOLUTION/DROPS;OPHTHALMIC	021009-001	Dec 8, 1999		DISCN	Yes	No
Micro Labs Ltd India	CROMOLYN SODIUM	cromolyn sodium	CONCENTRATE;ORAL	202745-001	Apr 4, 2013	AA	RX	No	No
Teva Pharms	CROMOLYN SODIUM	cromolyn sodium	SOLUTION;INHALATION	075271-001	Jan 18, 2000	AN	RX	No	Yes

Decreased Histamine Release Market Analysis and Financial Projection

The market for drugs that decrease histamine release, including antihistamines and mast cell stabilizers, is undergoing significant growth and innovation driven by rising allergy prevalence, technological advancements, and strategic patent protections. Here's an analysis of the market dynamics and patent landscape:

---

Market Dynamics

Growth Drivers

• Rising Allergy Prevalence: Allergic conditions affect 10-30% of the global population, with antihistamines dominating treatment. The global antihistamine market is projected to grow from $282.7 billion (2023) to $616 billion by 2033 (CAGR 8.1%)[1][3][6]. Mast cell stabilizers, targeting histamine release at its source, are expected to reach $3.3 billion by 2030 (CAGR 6.8%)[8][11].
• Shift to OTC Availability: Over 50% of H-1 antihistamines (e.g., loratadine, cetirizine) are now OTC, enhancing consumer access and driving $568 million in antihistamine sales by 2031[3][4][8].
• Non-Sedating Innovations: Second-generation antihistamines (less drowsiness) and mast cell-stabilizing eye drops (e.g., olopatadine) capture 58.3% of antihistamine sales[1][10][11].
• Expanding Indications: Antihistamines are repurposed for insomnia and anxiety, while mast cell stabilizers like masitinib target mastocytosis and sickle cell disease[5][7][14].

Regional Trends

• North America leads with 39.5% market share in mastocytosis treatments and dominates antihistamine consumption due to high allergy awareness[14][6].
• Asia-Pacific emerges as a growth hub, driven by increasing healthcare access and pollution-related allergy spikes[2][6].

Challenges

• Side Effects: First-generation antihistamines (e.g., diphenhydramine) face declining use due to sedation, while mast cell stabilizers report gastrointestinal and renal risks[2][8].
• Generic Competition: Patent expirations (e.g., H2-blocker Tagamet®) and generic entries reduce prices, pressuring revenue for originators[2][16].

---

Patent Landscape

Key Innovations

• Long-Term Exclusivity: AB Science secured EU patents for masitinib in mastocytosis (protection until 2036) and sickle cell disease (until 2040)[7][18].
• Novel Delivery Systems: Patents cover nanoparticle-based formulations (EP3359195A1) and ocular-targeted mast cell stabilizers (US20160346245A1)[13][10].
• Dual-Action Therapies: Olopatadine’s patents emphasize combined antihistamine/mast cell-stabilizing effects for allergic conjunctivitis[10].

Strategic Focus Areas

• Precision Medicine: Genetic targeting of histamine receptors (H1/H2) for tailored therapies[6][12].
• Biologics: Monoclonal antibodies against mast cell mediators (e.g., anti-IgE) are in clinical trials[9][14].
• Combo Therapies: 1,745 clinical trials explore antihistamines with corticosteroids or leukotriene inhibitors[9].

---

Future Outlook

• Market Expansion: Antihistamines will reach $950.9 million by 2031, while mast cell stabilizers hit $3.3 billion by 2030[1][8].
• Emerging Opportunities:
  • OTC Transition: Mast cell stabilizers eye drops (projected $650M by 2033)[11].
  • Biomarker-Driven R&D: 270 H1-receptor drugs in development for urticaria and allergic conjunctivitis[9][12].
  • Digital Health Integration: AI-driven dosing optimization and telehealth distribution[3][8].

Highlight: "The development of non-sedating antihistamines and mast cell-targeted biologics represents a paradigm shift in allergy management, combining safety with precision" [1][11].

References

1. https://straitsresearch.com/report/antihistamine-drugs-market
2. https://markwideresearch.com/autacoids-and-related-drugs-market/
3. https://market.us/report/antihistamines-market/
4. https://www.databridgemarketresearch.com/reports/global-antihistamine-drugs-market
5. https://www.futuremarketinsights.com/reports/antihistamine-market
6. https://www.coherentmarketinsights.com/industry-reports/global-antihistamine-drugs-market
7. https://www.biospace.com/press-releases/ab-science-receives-notice-of-allowance-for-european-patent-covering-masitinib-until-2040-in-the-treatment-of-sickle-cell-disease
8. https://www.credenceresearch.com/report/mast-cell-stabilizers-market
9. https://synapse.patsnap.com/blog/decoding-cyclizine-hydrochloride-a-comprehensive-study-of-its-randd-trends
10. https://www.belmorelaw.com/docs/default-source/case-documents/alcon-canada-inc.-v.-apotex-inc-.pdf?sfvrsn=629d9380_1
11. https://www.verifiedmarketreports.com/product/mast-cell-stabilizer-eye-drops-market/
12. https://www.frontiersin.org/journals/systems-neuroscience/articles/10.3389/fnsys.2012.00072/full
13. https://patents.google.com/patent/US20160346245A1/en
14. https://market.us/report/indolent-systemic-mastocytosis-treatment-market/
15. https://patents.google.com/patent/JPH06183991A/en
16. https://www.acs.org/education/whatischemistry/landmarks/cimetidinetagamet.html
17. https://patents.google.com/patent/WO2009148137A1/en
18. https://www.biospace.com/ab-science-announces-issuance-of-a-european-patent-for-masitinib-in-the-treatment-of-severe-mastocytosis-with-protection-until-2036